PL1737428T3 - Makrocząsteczkowe systemy dostarczania do nieinwazyjnego obrazowania, oceny i leczenia zapalenia stawów i innych chorób zapalnych - Google Patents

Makrocząsteczkowe systemy dostarczania do nieinwazyjnego obrazowania, oceny i leczenia zapalenia stawów i innych chorób zapalnych

Info

Publication number
PL1737428T3
PL1737428T3 PL05732710T PL05732710T PL1737428T3 PL 1737428 T3 PL1737428 T3 PL 1737428T3 PL 05732710 T PL05732710 T PL 05732710T PL 05732710 T PL05732710 T PL 05732710T PL 1737428 T3 PL1737428 T3 PL 1737428T3
Authority
PL
Poland
Prior art keywords
arthritis
evaluation
treatment
delivery systems
inflammatory diseases
Prior art date
Application number
PL05732710T
Other languages
English (en)
Inventor
Dong Wang
Jindrich Kopecek
Scott C. Miller
Pavla Kopecková
Original Assignee
University Of Utah Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Utah Research Foundation filed Critical University Of Utah Research Foundation
Publication of PL1737428T3 publication Critical patent/PL1737428T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL05732710T 2004-03-31 2005-03-30 Makrocząsteczkowe systemy dostarczania do nieinwazyjnego obrazowania, oceny i leczenia zapalenia stawów i innych chorób zapalnych PL1737428T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55804704P 2004-03-31 2004-03-31
PCT/US2005/010801 WO2005097073A1 (en) 2004-03-31 2005-03-30 Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases
EP05732710.8A EP1737428B1 (en) 2004-03-31 2005-03-30 Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases

Publications (1)

Publication Number Publication Date
PL1737428T3 true PL1737428T3 (pl) 2018-03-30

Family

ID=35124812

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05732710T PL1737428T3 (pl) 2004-03-31 2005-03-30 Makrocząsteczkowe systemy dostarczania do nieinwazyjnego obrazowania, oceny i leczenia zapalenia stawów i innych chorób zapalnych

Country Status (9)

Country Link
US (2) US10092662B2 (pl)
EP (2) EP3269394A1 (pl)
CA (1) CA2557448C (pl)
DK (1) DK1737428T3 (pl)
ES (1) ES2641570T3 (pl)
HU (1) HUE034923T2 (pl)
PL (1) PL1737428T3 (pl)
PT (1) PT1737428T (pl)
WO (1) WO2005097073A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1737428T3 (pl) 2004-03-31 2018-03-30 University Of Utah Research Foundation Makrocząsteczkowe systemy dostarczania do nieinwazyjnego obrazowania, oceny i leczenia zapalenia stawów i innych chorób zapalnych
EP1647283A1 (en) * 2004-10-12 2006-04-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Polymeric contrast agent
EP1902734A1 (en) * 2006-09-25 2008-03-26 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts uPAR selective contrast agent for magnetic resonance imaging
CN101265331B (zh) * 2007-03-12 2010-10-13 中国科学院化学研究所 Peg改性phpma材料及其制备方法
DE102007041625A1 (de) * 2007-09-03 2009-03-05 Sinn, Hannsjörg, Dr. Neue Gelatine-Wirkstoff-Konjugate
CN102740795B (zh) * 2009-09-09 2016-11-02 内布拉斯加大学董事委员会 用于检测和治疗植入物松动和骨质溶解的组合物和方法
US20110158901A1 (en) * 2009-12-29 2011-06-30 Swadeshmukul Santra Chitosan-based nanoparticles and methods for making and using the same
CA2825424A1 (en) 2010-02-08 2011-08-11 Board Of Regents Of The University Of Nebraska Biomineral and metal binding liposomes, their synthesis, and methods of use thereof
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
EP2621950A4 (en) 2010-09-27 2015-09-02 Janssen Biotech Inc ANTIBODIES FOR BINDING HUMAN COLLAGEN II
US9149537B2 (en) 2010-11-04 2015-10-06 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of traumatic brain injury
BR112015000174A2 (pt) 2012-07-05 2017-06-27 Taiwan Liposome Co Ltd método para o tratamento da artrite
WO2017083794A1 (en) 2015-11-12 2017-05-18 Board Of Regents Of The University Of Nebraska Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof
US10905783B2 (en) 2015-11-27 2021-02-02 Michal RIVLIN Glucosamine and derivatives thereof in imaging
CN105797174B (zh) * 2016-01-22 2019-01-11 复旦大学附属肿瘤医院 一种基于纳米氧化石墨烯的磁共振成像造影剂及其制备方法
EP3860660A4 (en) * 2018-10-05 2023-01-25 Texas Heart Institute IMAGING MEDIA AND METHODS OF USE
US12138274B2 (en) 2018-11-08 2024-11-12 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of peripheral artery disease and cardiopulmonary diseases
CN113415908B (zh) * 2021-05-19 2022-04-29 河北津宏化工有限公司 一种改性水解聚马来酸酐水处理剂及其制备方法
CN116076438B (zh) * 2023-03-21 2024-01-30 湖南中医药大学 类风湿关节炎合并间质性肺病动物模型及其构建方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034040A (en) 1971-05-24 1977-07-05 Pfizer Inc. Xylene-diamines as antiviral agents
US6217911B1 (en) * 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
GB8500209D0 (en) * 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
DK110188D0 (da) 1988-03-02 1988-03-02 Claus Selch Larsen High molecular weight prodrug derivatives of antiinflammatory drugs
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
ATE318176T1 (de) * 1998-08-31 2006-03-15 Julian L Ambrus Verfahren zur entfernung von hiv und anderen viren aus blut
US6436386B1 (en) * 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
US20040043030A1 (en) * 2001-07-31 2004-03-04 Immunomedics, Inc. Polymeric delivery systems
CA2491427A1 (en) * 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
AU2002953073A0 (en) 2002-11-21 2003-01-16 Access Pharmaceuticals Australia Pty Limited Amplification of biotin-mediated targeting
PL1737428T3 (pl) 2004-03-31 2018-03-30 University Of Utah Research Foundation Makrocząsteczkowe systemy dostarczania do nieinwazyjnego obrazowania, oceny i leczenia zapalenia stawów i innych chorób zapalnych

Also Published As

Publication number Publication date
WO2005097073A1 (en) 2005-10-20
ES2641570T3 (es) 2017-11-10
EP1737428B1 (en) 2017-08-30
DK1737428T3 (en) 2017-10-09
WO2005097073A8 (en) 2005-12-08
US10172962B2 (en) 2019-01-08
CA2557448A1 (en) 2005-10-20
HUE034923T2 (en) 2018-03-28
EP3269394A1 (en) 2018-01-17
CA2557448C (en) 2015-06-23
US10092662B2 (en) 2018-10-09
EP1737428A4 (en) 2010-12-22
PT1737428T (pt) 2017-10-02
US20080159959A1 (en) 2008-07-03
US20180207296A1 (en) 2018-07-26
EP1737428A1 (en) 2007-01-03

Similar Documents

Publication Publication Date Title
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
IL184425A0 (en) Cxcr4 antagonists for the treatment of medical disorders
WO2007147019A3 (en) Il-17 and il-23 antagonists and methods of using the same
EP2712930A3 (en) Interferon alpha-induced pharmacodynamic markers
AU2003239531A8 (en) Protein cages for the delivery of medical imaging and therapy
AU2003220317A8 (en) Methods and drug delivery systems for the treatment of orofacial diseases
IL196745A (en) Idabanon for use in providing mucosal pathways to treat disease
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
EP1846080A4 (en) SYSTEM AND METHOD FOR DISTRIBUTING THERAPEUTIC AGENT
IL204584A0 (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
IL190841A0 (en) Pharmaceutical compositions and diagnostic methods for inflammatory skin diseases, disorders or conditions
GB0410399D0 (en) The treatment of respiratory disease
EP1737428A4 (en) MACROMOLECULAR DISPENSING SYSTEMS FOR THE NON-INVASIVE PRESENTATION, INVESTIGATION AND TREATMENT OF ARTHRITIS AND OTHER INFLAMMATORY DISEASES
GB0410398D0 (en) The treatment of respiratory disease
IL194880A (en) Aminazole amine derivatives, their use in the treatment of diseases and pharmaceuticals containing them
EP2056857A4 (en) PHARMACEUTICAL COMPOSITIONS WITH CCL2 AND THEIR USE IN THE TREATMENT OF INFLAMMATION
IL178827A0 (en) Use of reboxetine for the treatment of pain
ZA200800981B (en) Use of SDF-1 for the treatment and/or prevention of neurological diseases
PL1835907T3 (pl) Leki do leczenia lub zapobiegania chorobom zwłóknieniowym
EP1724271A4 (en) PREVENTIVE AND / OR THERAPEUTIC AGENT AGAINST NEUTROPHIC INFLAMMATORY DISEASE
IL193943A0 (en) The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
EP1773882A4 (en) DIAGNOSIS AND TREATMENT OF SIGLEC-6 ASSOCIATED DISEASES
WO2006116311A3 (en) Opioid receptor agonist compounds and their use in treatment of pain
WO2006124477A3 (en) Combination therapy with inhibitors of hmgb and caspase for the treatment of inflammatory diseases